Ozempic & Wegovy - The Perfect Storm?

5 snips

Nov 9, 2024

Dive into the murky waters of weight loss drugs, exploring the troubling history of appetite suppressants and their current impact on society. Discover the obesity epidemic's staggering rise and the failing government initiatives tackling the issue. Unpack the fierce competition among pharmaceutical giants like Novo Nordisk, fueled by market dynamics and regulatory challenges. Analyze the intricate dance between drug approval processes and industry influence, revealing a potentially volatile perfect storm in obesity treatment.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

ANECDOTE

Mediator Scandal

In the 1980s, French women used Mediator for weight loss after childbirth.
It caused heart valve issues and deaths, leading to investigations and legal action against the drug company and regulators.

INSIGHT

Ozempic vs. Wegovy

Ozempic and Wegovy are the same drug (semaglutide) but prescribed for different purposes (diabetes vs. weight loss).
High demand, especially for Ozempic, has led to shortages and advice against new weight-loss prescriptions.

INSIGHT

Obesity Epidemic

Obesity is a growing problem in developed countries, with the US and Australia having the highest percentages.
This "obesity epidemic" has significant economic impacts, costing billions annually.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

Welcome to Investigating Ozempic.

To see the fully formed picture of the new weight loss drugs I've had to dig deep. Years of research and interviews with scientists and health professionals. This is no junior jigsaw puzzle - it's a pretty tricky one - so get on board!

This week we follow the twists... and turn over three major puzzle pieces of the hidden picture to reveal the truth behind the new weight loss drugs. We look at Government Regulators, Drug Companies and the Worldwide Obesity Epidemic.

We ask the Question: Is this potentially the Perfect Storm - Because we have never had these three events coincide before.

Is it a small rain shower or a Stage 5 hurricane? - it's anyone's guess.

Plus we take a look at what to expect from the Podcast.

Episodes will drop weekly approximately.

Contact

investigatingozempic@gmail.com

Special Note

In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECTS of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of advice on if these drugs are suitable for Diabetics. I am not a qualified health care professional.

Legal and Medical Disclaimer:

The Investigating Ozempic podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.

Every care has been taken to obtain accurate information including reaching out to Novo Nordisk for comment - which so far has remained unanswered. We encourage Novo Nordisk to contact me and correct any discrepancies that have been made accidentally and in good faith by the author. This podcast contains my personal opinion which is solely my own and not intended to be construed in any other manner.

Copyright

All rights reserved by Bernadette Fisers. Material in the podcast and any content therein is subject to copyright under Australian law and through international treaties, and applicable law in other countries.

Unless otherwise indicated, we (and/or our third-party licensors) own the copyright and other intellectual property rights in the recording, text, graphics, information, designs, data and other content in this document.